Evidence map›Paper›PMID 42556340›Full record

ArticleCell reports. Medicine2026

Phase 1 study of intracranial T cell therapy with pemetrexed for refractory brain metastases and glioblastomas.

Congcong Li, Shuang Wang, Xiumei Rong, Chuxiong Zeng, Feifei Huo, Haiyang Zhao, Dazhao Xu, Lina Hu, Linyao Lu, Bo Sun and 11 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Congcong LiDepartment of Medical Oncology, Fudan University Pudong Medical Center, Shanghai 201399, P.R. China; Solid Tumor Cell Therapy Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China.
Shuang WangState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China; School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing 100049, P.R. China.
Xiumei RongDepartment of Medical Oncology, Beijing Zhongguancun Hospital, Chinese Academy of Sciences, Beijing 100190, P.R. China.
Chuxiong ZengDepartment of Medical Oncology, Fudan University Pudong Medical Center, Shanghai 201399, P.R. China.
Feifei HuoDepartment of Medical Oncology, Beijing Zhongguancun Hospital, Chinese Academy of Sciences, Beijing 100190, P.R. China.
Haiyang ZhaoDepartment of Medical Oncology, Beijing Zhongguancun Hospital, Chinese Academy of Sciences, Beijing 100190, P.R. China.
Dazhao XuDepartment of Medical Oncology, Beijing Zhongguancun Hospital, Chinese Academy of Sciences, Beijing 100190, P.R. China.
Lina HuDepartment of Medical Oncology, Fudan University Pudong Medical Center, Shanghai 201399, P.R. China.
Linyao LuDepartment of Medical Oncology, Fudan University Pudong Medical Center, Shanghai 201399, P.R. China.
Bo SunDepartment of Medical Oncology, Fudan University Pudong Medical Center, Shanghai 201399, P.R. China; Solid Tumor Cell Therapy Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China.
Yanhua YuanDepartment of Medical Oncology, Fudan University Pudong Medical Center, Shanghai 201399, P.R. China.
Xiaoli WangDepartment of Medical Oncology, Beijing Zhongguancun Hospital, Chinese Academy of Sciences, Beijing 100190, P.R. China.
Xinna ZhouDepartment of Clinical Trial and Medical Management, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, P.R. China.
Amy HobeikaDepartment of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Michael A MorseDepartment of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Guanghui MaState Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China; School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing 100049, P.R. China. Electronic address: ghma@ipe.ac.cn.
Li RenDepartment of Neurosurgery, Fudan University Pudong Medical Center, Shanghai 201399, P.R. China. Electronic address: slysw@sina.com.
Jiyu LiDepartment of Medical Oncology, Fudan University Pudong Medical Center, Shanghai 201399, P.R. China. Electronic address: lijiyu@fudan.edu.cn.
Herbert Kim LyerlyDepartment of Surgery, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: kim.lyerly@duke.edu.
Zhijun BaoCenter of Applied Therapeutic Oncology, Fudan University Huadong Medical Center, Shanghai 200040, P.R. China. Electronic address: zhijunbao@fudan.edu.cn.
Jun RenDepartment of Medical Oncology, Fudan University Pudong Medical Center, Shanghai 201399, P.R. China; Solid Tumor Cell Therapy Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, P.R. China; Department of Medical Oncology, Beijing Zhongguancun Hospital, Chinese Academy of Sciences, Beijing 100190, P.R. China; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA; Center of Applied Therapeutic Oncology, Fudan University Huadong Medical Center, Shanghai 200040, P.R. China. Electronic address: jun.ren@duke.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic options remain limited for advanced intracranial malignancies, including brain metastases and glioblastomas, particularly in patients ineligible for surgery, radiotherapy, or systemic therapies. This phase 1 study evaluates the safety and feasibility of intracranial administration of low-dose pemetrexed followed by RetroNectin-activated killer cells (RAKs) and interleukin 2 via an Ommaya reservoir (collectively referred to as SCOPE-T) in 25 patients with refractory intracranial malignancies. Nineteen patients completed at least one treatment cycle, and 17 received the maximum tested RAK dose (5 × 10

Indexed as

Brain NeoplasmsGlioblastomaPemetrexedT-LymphocytesAdultAgedFemaleHumansInterleukin-2MaleMiddle AgedInterleukin-2Pemetrexedadvanced intracranial malignanciesbrain metastasescell therapyintracranial administrationpemetrexedRetroNectin-activated killer cells

Identifiers

PMID42556340
PMCPMC13522775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.